Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Novo Nordisk Built a Moat in Diabetes and Weight Loss
Transcript
- Lucas: If I told you that Europe's most valuable company — worth over six hundred billion dollars — is a Danish pharmaceutical firm that spent a century focused mostly on diabetes, you might raise an eyebrow. Luna: Novo Nordisk. It's not exactly a household name in the US the way Apple or Microsoft is, but yeah, it's now bigger than the entire Danish economy by market cap. Lucas: That's right. And its moat is one of the most fascinating in all of business right now. We're talking about a company that controls roughly half the global insulin market — but that's almost the boring part. The real story is what happened when they bet big on a class of drugs called GLP-1 receptor agonists. Luna: Ozempic, Wegovy — those names have entered the cultural lexicon. But the depth of the moat goes way beyond just having a popular drug. Lucas: If these conversations have moved your work forward in some small way, honestly, if today was worth a coffee to you, that's the link — buy me a coffee dot com slash fexingo. It's what keeps this thing ad-free and independent. Luna: Yeah, it's a small gesture that makes a big difference for us. And we're grateful. Lucas: Alright, so let's lay out the moat. Novo Nordisk was founded in 1923, the same year insulin was first commercialized. From the beginning, they focused on protein engineering — making insulin molecules that work better in the body. That expertise carried forward for decades. Luna: And that's not something you can just buy off the shelf. It's decades of accumulated knowledge in a very specific discipline. Lucas: Exactly. By the 1990s, they had developed a long-acting insulin called Levemir, and then an ultra-long acting insulin called Tresiba. But the real breakthrough came when they started working on GLP-1 — a naturally occurring hormone that stimulates insulin secretion and slows gastric emptying. Luna: So they took their protein engineering skills and applied them to a different molecule. That's a classic adjacency move. Lucas: Precisely. In 2010, they launched Victoza, a once-daily GLP-1 injection for diabetes. It was good, but the real step change came when they engineered semaglutide — the molecule behind Ozempic and Wegovy. Semaglutide is designed to last much longer in the body, so it can be taken once weekly. And it turned out to have remarkable weight loss effects. Luna: That's where the moat gets deep. Because manufacturing these drugs is incredibly difficult. GLP-1 drugs are peptides — chains of amino acids — produced via recombinant DNA technology. It's not like making a small molecule pill. Lucas: Right. And Novo Nordisk has spent years building out massive production capacity. They have dedicated manufacturing facilities in Denmark, the US, Brazil, China, and France. As of early 2026, they're investing over six billion dollars to expand production further. That's a capital expenditure moat that competitors can't easily match. Luna: Eli Lilly is trying. They have tirzepatide — Mounjaro and Zepbound — which is also a GLP-1 drug, and some data suggests it's even more effective for weight loss. But they're supply constrained. They simply can't make enough yet. Lucas: That's the thing. Novo has a roughly ten-year head start in GLP-1 manufacturing. They've been refining the fermentation and purification processes since well before Ozempic launched. It's not just about having the patent — it's about having the factory running at scale with high yield. Luna: And the patents themselves are a layer. Semaglutide's composition of matter patents don't expire until 2032 in the US and 2033 in Europe. But as we've seen with other pharma companies, patents can be challenged. The manufacturing moat is harder to circumvent. Lucas: There's also a clinical moat. Novo has run huge cardiovascular outcomes trials showing that semaglutide reduces heart attack and stroke risk in overweight patients — even those without diabetes. That's data that takes years to generate, and regulators use it to expand labels. Competitors have to run their own trials, which is enormously expensive and time-consuming. Luna: So you've got the protein engineering expertise, the manufacturing scale, the clinical data, and the brand recognition among prescribers. That's a quadruple moat. Lucas: And the brand moat is real. Doctors have been prescribing Novo insulins for decades. They trust the company. When a new GLP-1 comes along from a competitor, the default is often to prescribe the one with the longest track record — Ozempic. Luna: Now, let's talk about the market itself. The global prevalence of diabetes is expected to grow from about 530 million adults today to over 700 million by 2045. And obesity affects nearly a billion people. So the addressable market is enormous. Lucas: Novo's obesity franchise alone, Wegovy, has been growing at a compound annual growth rate of over 25 percent. In the first quarter of 2026, it generated nearly two billion dollars in revenue. That's approaching blockbuster status — actually, it's already beyond blockbuster. Luna: And they're not stopping. They're working on an oral version of semaglutide, which would be a game-changer because a pill is easier to manufacture and distribute than an injectable. But they've had some challenges getting the bioavailability high enough. Lucas: That's the next frontier. If they can crack oral semaglutide, the moat gets even wider. But even if they don't, the injectable formulations have years of runway. Luna: One risk that people talk about is the possibility of competing drugs from smaller biotechs using new modalities like oral small molecules or even gene therapies. But those are years away from approval, if they work at all. Lucas: Right. The bar is incredibly high. Any new therapy has to show it's at least as effective as semaglutide, and preferably with better tolerability or oral dosing. That's a tall order. Luna: And then there's the pricing risk. These drugs are expensive — Ozempic lists for about a thousand dollars a month in the US. If governments or insurers push back hard, that could compress margins. But Novo has managed pricing pressures before. They have a long history of negotiating with payers. Lucas: Also, the volume growth is so strong that even if prices come down a bit, the revenue trajectory remains steep. And Novo has a very strong balance sheet — they fund their own R&D, so they're not dependent on external capital. That's another moat — financial independence. Luna: Let's step back and think about what makes this moat durable in the long term. Is it the patents, the manufacturing, the clinical data, or something else? Lucas: I think it's the combination, but if I had to pick one, it's the manufacturing and process expertise. Patents expire, but the ability to produce a complex biologic at scale with high purity and yield is something that takes a decade or more to build. Novo has that, and they're investing more every year. Luna: And they've also built a proprietary delivery device — the FlexPen and the newer injector pens. That's a small but real barrier: switching costs for patients and clinicians who are familiar with the device. Lucas: Exactly. So the moat is layered. And that's what makes Novo Nordisk such a compelling case study for competitive advantage. It's not just one thing — it's a system. Luna: Alright, so what's the one concrete takeaway for our listeners? If you're building a business, what can you learn from Novo? Lucas: I'd say, pick a domain that's hard — really hard — and commit to it for decades. Novo started with insulin because diabetes was a massive, underserved disease. They stayed focused, built deep expertise, and when a new opportunity emerged that played to their strengths, they pounced. The moat came from consistency and reinvestment. Luna: Not flashy, but incredibly effective. Lucas: Right. And worth thinking about as we consider our own strategies, whether we're running a startup or a division inside a larger firm. Luna: Next time on Business Strategy Talks, we'll look at a company that has built a moat on an entirely different basis — network effects in the logistics industry. Lucas: That sounds good. Until then, keep thinking about what makes your business hard to replicate.